Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specialising in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, announced on Thursday that it has been honoured with multiple awards by Top Workplaces and the US News & World Report 2024-2025 ratings.
Top Workplaces has added Zynex to its 2024 Top Workplaces - Manufacturing list. US News & World Report has also offered Zynex with three awards under its 'Best Companies to Work For' in 2024-2025 ratings, including 'Best in Pharmaceuticals and Health Products', 'Best Companies' and 'Best in the West'.
Thomas Sandgaard, Founder, Chairman, and CEO of Zynex, said, 'We are privileged to be recognized by both Top Workplaces and US News & World Report, recognizing the emphasis we place on our team by developing leaders and sustaining employee well-being. We continue to place a high priority on supporting our employees to advance in their careers and maintain work/life balances. By improving on our team's health, benefits and comfort, we can in turn empower them to accelerate progress on business goals including order growth, FDA approvals of next-generation devices, and new therapy products.'
Azenta names new president and CEO
PHC announces launch of LiCellMo live cell metabolic analyzer targeting CGT advancements
Heron Therapeutics names new chief business officer
Expanse Medical names new chief executive officer and FlowPhysix board member
Qaelon Medical names new chief executive officer
Johnson & Johnson agrees acquisition of V-Wave
Nightingale Health gains UKCA certification and expands with new laboratory
Talphera enrols first subject in NEPHRO CRRT study
China Pharma Holdings anticipates launch of Dry Eye Disease Therapeutic Device in early 2025
SOPHiA DDM Platform achieves IVDR certification, enhancing diagnostic precision
Medtronic reports FDA approval of Simplera CGM; partners with Abbott
OncoBeta expands Rhenium-SCT (Skin Cancer Therapy) treatment services in Italy
Labcorp's PGDx elio plasma focus Dx receives US FDA De Novo marketing authorisation
Verici Dx announces completion of Thermo Fisher Scientific licensing agreement